Published by the IC
nternational M I
yeloma FT
oundation
ING
Special Editio S
n: ASH 2010
American Society of Hematology (ASH) 2010
Novel Therapies Presentations Issue
Welcome to the International Myeloma Foundation's (IMF) special edition of CITINGS, our premiere publication
featuring the most up-to-date information on myeloma treatment and diagnostics.
This issue focuses on presentations at the Annual American Society of Hematology Meeting on December 4-7, 2010
in Orlando, Florida. For your convenience, and to help you better navigate the conference, we have listed below,
in chronological order by presentation (oral or poster) those presentations relevant to multiple myeloma and
related pathologies.
As always, please feel free to contact the IMF at (800) 452-2873 (CURE) or at www.myeloma.org.
Susie Novis, President, IMF
Novel Therapies Presentations ASH 2010
Saturday, December 4th
Achievement of Complete Response Is a Strong Prognostic Factor In Elderly Newly Diagnosed Myeloma:
Retrospective Analysis of 1175 Patients
Francesca Gay, Alessandra Larocca, P.W. Wijermans, Sara Bringhen, Tommasina Guglielmelli, Martijn R. Schaafsma, Giulia Benevolo,
Vincenzo Callea, Luca Baldini, Fortunato Morabito, Mariella Grasso, Giuseppe Torelli, Manuela Rizzo, Monica Galli, Grazia Sanpaolo,
Clotilde Cangialosi, Paola Omedè, Mario Boccadoro, Pieter Sonneveld, and Antonio Palumbo
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1949
Poster Board: I-929
Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents
Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study
Joyce Habib, Neil Dunavin, Gary Phillips, Patrick Elder, Meaghan Tranovich, Don M. Benson Jr., Craig C. Hofmeister, John C. Byrd,
Steven M. Devine, and Yvonne Efebera
Poster Session: Clinical Results - Autologous Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1343
Poster Board: I-323
Analysis of Serial Body Height Measurements In Total Therapy 2 (TT2, Control v Thalidomide Arm) and
Total Therapy 3 (A: VTD Maintenance; B: VRD Maintenance) as a Guide to Overall Bone Health In Multiple Myeloma (MM)
Alan Mitchell, Antje Hoering, Frits van Rhee, Elias J. Anaissie, John Crowley, and Bart Barlogie
Poster Session: Clinical Results - Autologous Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1354
Poster Board: I-334
www.myeloma.org
(800) 452 - CURE (2873)
Funded by an unrestricted educational grant from Celgene Corporation and Onyx Pharmaceuticals
Characteristics of Patients Presenting with Secondary Myelodysplastic Syndrome During Treatment with Lenalidomide
for Relapsed/Refractory Multiple Myeloma: 5q Deletions Can Be Observed
Rashmi S. Goswami, David Barth, Esther Masih-Khan, Haowei (Linda) Sun, Manoj Mathew, Christine Chen, Suzanne Trudel,
Suzanne Kamel-Reid, and Donna E. Reece
Poster Session: Myelodysplastic Syndromes: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1876
Poster Board: I-856
Combined Bendamustine, Prednisolone and Lenalidomide (RBP) In Refractory or Relapsed Multiple Myeloma.
First Results of a Phase I Clinical Trial
Wolfram Pönisch, Simone Heyn, Ina Wagner, Martin Mohren, Franz-Albert Hoffmann, Frank Schüler, Marion Schmalfeld,
Haifa K. Al-Ali, Nadja Jäkel and Dietger W. Niederwieser
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1971
Poster Board: I-951
Combining the Ras Inhibitor Salirasib and Proteasome Inhibitors: A Potential Treatment for Multiple Myeloma
Shira Yaari-Stark, Yael Nevo-Caspi, Jasmine Jacob-Hircsh, Gideon Rechavi, Arnon Nagler, and Yoel Kloog
Poster Session: Molecular Pharmacology, Drug Resistance: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1810
Poster Board: I-790
The Efficacy and Safety of RAD (Lenalidomide, Adriamycin and Dexamethasone) In Newly Diagnosed Multiple Myeloma
First Results of a Phase II Trial by the German DSMM Group
Stefan Knop, Christian Langer, Monika Engelhardt, Lars O. Muegge, Albrecht Reichle, Christoph Röllig, Martin Gramatzki,
Wolf Roesler, Max S. Topp, Carmen Wesemeier, Bernd Hertenstein, Isrid Sturm, Tobias Dechow, Martin Kortüm,
Marianne Sauerwein, Hermann Einsele, and Ralf Bargou
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1945
Poster Board: I-925
Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy
for Newly Diagnosed Multiple Myeloma
Sumit Madan, Martha Lacy, Angela Dispenzieri, Morie Gertz, Francis Buadi, Suzanne R. Hayman, Kristen Detweiler-Short,
David Dingli, Steven Zeldenrust, John Lust, Philip R. Greipp, S. Vincent Rajkumar, and Shaji Kumar
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1964
Poster Board: I-944
Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients
with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase I Study
Sagar Lonial, Ravi Vij, Jean-Luc Harousseau, Thierry Facon, Philippe Moreau, Xavier Leleu, Amitabha Mazumder,
Jonathan L Kaufman, Christopher E Westland, Claire Tsao, Anil K. Singhal, and Sundar Jagannath
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1936
Poster Board: I-916
www.myeloma.org
(800) 452 - CURE (2873)
Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts
at the Start of Each Cycle
Pooja S. Raibagkar, Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, David Irwin, Edward A. Stadtmauer, Thierry Facon,
Jean-Luc Harousseau, Dina Ben-Yehuda, Sagar Lonial, Hartmut Goldschmidt, Donna E. Reece, Jesus F. San Miguel, Joan Blade,
Mario Boccadoro, Rachel Neuwirth, Dixie-Lee Esseltine, Kenneth C. Anderson and Nikhil C. Munshi
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1963
Poster Board: I-943
High Dose Intravenous Busulfan (BU) and Melphalan (MEL ) Followed by Bortezomib (BTZ) as Conditioning with Autologous
Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM)
Tulio E. Rodriguez, Patrick J. Stiff, Scott E. Smith, Jonathan L. Kaufman, Mary Lee, Mala Parthasarathy, Zachary M. Earley,
Sagar Lonial, and David H. Vesole
Poster Session: Clinical Results - Autologous Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1355
Poster Board: I-335
Impact of Response to Thalidomide, Lenalidomide or Bortezomib Containing Induction Chemotherapy on Outcomes
of Multiple Myeloma Patients Undergoing Autologous Transplantation A Multicenter Analysis
Farrukh Awan, Salman Osman, Samith Thomas Kochuparambil, Scot Remick, Jame Abraham, Michael Craig, Anand P. Jillella,
and Sayed Mehdi Hamadani
Poster Session: Clinical Results - Autologous Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1351
Poster Board: I-331
Incidence and Characteristics of Secondary Myelodysplastic Syndrome Developing During Lenalidomide-Based Regimens
In Relapsed and/or Refractory Multiple Myeloma Patients
Donna E. Reece, Esther Masih-Khan, Rashmi S. Goswami, Sharon Fung, David Barth, Christine Chen, Vishal Kukreti,
Haowei (Linda) Sun, Saima Dean and Suzanne Trudel
Poster Session: Myelodysplastic Syndromes: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1877
Poster Board: I-857
The Introduction of Novel Agents Improves Outcomes of Young Patients with Myeloma (MM) Treated
with Autologous Stem Cell Transplant (ASCT)
Radovan Saso, Kevin D. Boyd, Kabir Mohammed, Ping Wu, Jennifer Treleaven, Faith E. Davies, and Gareth J. Morgan
Poster Session: Clinical Results - Autologous Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1348
Poster Board: I-328
Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma
(MM): Final Results of Phase I/II MMRC Trial
Andrzej J. Jakubowiak, Donna E. Reece, Craig C. Hofmeister, Sagar Lonial, Todd M. Zimmerman, Erica L. Campagnaro,
Robert L. Schlossman, Jacob P. Laubach, Noopur Raje, Tara B. Anderson, Kent A. Griffith, Melissa A. Hill, Colleen K. Harvey,
Sandra Wear, Jennifer Barrickman, Craig L. Tendler, Dixie-Lee Esseltine, Susan L. Kelley, Mark S. Kaminski, Kenneth C. Anderson,
and Paul G. Richardson
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1937
Poster Board: I-917
www.myeloma.org
(800) 452 - CURE (2873)
Lenalidomide Enhances Clonogenic Activity, Proliferation and Erythroid Lineage Commitment of CD34+ Progenitor Cells
While It Is Cytotoxic to CD34- Accessory Cells
Prakash Vishnu, Athena Paulsen, Vivek Roy and Abba Zubair
Poster Session: Cell Processing: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1184
Poster Board: I-164
Lenalidomide (LEN) Therapy In Combination with Dexamethasone (DEX) Is Associated with a Low Incidence of Viral Infections
Rachid Baz, Sagar Lonial, Mohamad Hussein, Arlene S. Swern, and Meletios A. Dimopoulos
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1950
Poster Board: I-930
Long-Term Maintenance with Lenalidomide Improves Progression Free Survival In Myeloma Patients
with High-Risk Cytogenetics: An IFM Study
Hervé Avet-Loiseau, Denis Caillot, Gerald Marit, Valerie Lauwers-Cances, Murielle Roussel, Thierry Facon, Cyrille Hulin,
Thierry Lamy, Brigitte Pegourie, Hervé Maisonneuve, Laurent Garderet, Philippe Moreau, Anne-Marie Stoppa, Mamoun Dib,
Jerome Jaubert, Philippe Casassus, Claire Mathiot, Jean-Luc Harousseau, Philippe Moreau, and Michel Attal
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1944
Poster Board: I-924
Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy
In Patients with Relapsed/Refractory Myeloma, Who Are Aged 60 Years or Have Renal Impairment:
Planned Interim Results of a Prospective Multicentre Phase II Trial
Hang Quach, Liam Fernyhough, Ross Henderson, Gillian Corbett, Kevin Lynch, David Ritchie, Simon J. Harrison, and H. Miles Prince
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1961
Poster Board: I-941
MAGE-C1/CT7 Inhibition Increases Myeloma Cell Line Sensitivity to Bortezomib-Induced Apoptosis:
New Target for Myeloma Therapy?
Fabricio de Carvalho, Erico T. Costa, Anamaria A. Camargo, Juliana C. Gregorio, Cibele Masotti, Valeria C.C. Andrade,
Bryan E. Strauss, Otavia L. Caballero, Djordje Atanackovic, and Gisele W.B. Colleoni
Poster Session: Myeloma - Biology and Pathophysiology, excluding Therapy: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1908
Poster Board: I-888
Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine,
Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma
Aleksandr Lazaryan, Rachid Baz, Mohamad A. Hussein Jr., Paul Elson, Beth Faiman, Becky Habecker, Mary Ann Karam, Janice Reed,
Kimberly Hamilton, Kellie Bruening, Gordan Srkalovic, Steven Andresen, Matt Kalaycio, John William Sweetenham, Ronald Sobecks,
Robert Dean, Robert Knight, Jerome B. Zeldis, and Frederic J. Reu
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1967
Poster Board: I-947
www.myeloma.org
(800) 452 - CURE (2873)
A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and
Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients
Antonio Palumbo, Patrizia Falco, Giulia Benevolo, Davide Rossi, Angelo Michele Carella, Tommasina Guglielmelli, Alberto Rocci,
Lorenzo De Paoli, Mariella Grasso, Maria Letizia Mosca Siez, Eugenio Piro, Simona Caltagirone, Francesca Gay, Federica Cavallo,
Gianluca Gaidano, and Mario Boccadoro
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1940
Poster Board: I-920
Multiparameter Flow Cytometry Analysis of Peripheral Blood T, NK and Dendritic Cells From High-Risk Smoldering
Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone
Bruno Paiva, Lucía López Corral, María Belén Vidriales, Luis Ignacio Sánchez Abarca, Miguel T. Hernandez, Joan Bargay,
Javier De La Rubia, Pilar Giraldo, Ana Isabel Teruel, Laura Rosiñol, Albert Oriol, Jose Hernández, Felipe de Arriba, Graça Esteves,
Jose Antonio Pérez Simón, María Victoria Mateos, and Jesus F. San Miguel
Poster Session: Myeloma - Biology and Pathophysiology, excluding Therapy: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1906
Poster Board: I-886
Outcomes Following Salvage Autologous Stem Cell Transplant for Multiple Myeloma
Oral and Poster Abstracts
Daniel E. Fein, Hani Hassoun, Raymond L. Comenzo, Alex Lesokhin, Nikoletta Lendvai, David Chung, Adam Cohen,
Michael A. Rosenzweig, Danielle Chimento, Xiaoyu Jia, Stephen Nimer, Sergio Giralt, and Heather Landau
Poster Session: Clinical Results - Autologous Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1353
Poster Board: I-333
Phase I Study of Lorvotuzumab Mertansine (IMGN901) In Combination with Lenalidomide and Dexamethasone
In Patients with CD56-Positive Relapsed or Relapsed/Refractory Mulitple Myeloma - A Preliminary Safety and
Efficacy Analysis of the Combination
Jesus G. Berdeja, Sikander Ailawadhi, Ruben Niesvizky, Jeffrey L. Wolf, Sybil H. Zildjian, James O'Leary and Asher Chanan-Khan
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1934
Poster Board: I-914
A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory
Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population
Paul Richardson, Donna Weber, Constantine S. Mitsiades, Meletios A. Dimopoulos, Jean-Luc Harousseau, Jennifer Houp,
Thorsten Graef, Christine K. Gause, Catriona Byrne, Kenneth C. Anderson, and David Siegel
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1951
Poster Board: I-931
Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory
Multiple Myeloma
Irene Ghobrial, Abdel Kareem A. Azab, Jacob P. Laubach, Ranjit Banwait, Meghan Rourke, Phong Quang, Nikhil C. Munshi,
Robert L. Schlossman, Stacey Chuma, Janet Kunsman, Diane Warren, Amy Sam, Eric Still, Brittany Morgan, Kenneth C. Anderson,
and Paul G. Richardson
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1943
Poster Board: I-923
www.myeloma.org
(800) 452 - CURE (2873)
Phase I Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone
In Relapsed/Refractory Multiple Myeloma
Jatin J. Shah, Robert Z. Orlowski, Raymond Alexanian, Michael Wang, Sheeba Thomas, Muzaffar H. Qazilbash, Simrit Parmar,
Nina Shah, Qaiser Bashir, Uday Popat, and Donna Weber
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1948
Poster Board: I-928
Phase II Clinical Trial of Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP)
for Newly Diagnosed Multiple Myeloma Patients
Attaya Suvannasankha, Sherif Farag, Robin Obryant, Lisa Wood, Nicole Porter and Rafat Abonour
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1970
Poster Board: I-950
A Pilot Study of Melphalan, Lenalidomide and Dexamethasone In AL Amyloidosis: Interim Results
Anosheh Afghahi, Wesley Witteles, Ronald Witteles, Michaela Liedtke, Richard Lafayette, Sally Arai, and Stanley L. Schrier
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1946
Poster Board: I-926
Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments In Patients
with Relapsed or Refractory Multiple Myeloma: Evaluation of Peripheral Neuropathy In the First 1,011 Patients
Michel Delforge, Igor W. Blau, Miguel T. Hernandez, Roman Hájek, Luciano Masini, Henk Lokhorst, Giacinto La Verde,
Laurence Sanhes, Javier de la Rubia, Janine Collins, Barbara Rosettani, Nancy A. Brandenburg, and Renato Zambello
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1939
Poster Board: I-919
Primary Therapy of Waldenström's Macroglobulinemia (WM) with Weekly Bortezomib, Low-Dose Dexamethasone
and Rituximab (BDR): A Phase II Study of the European Myeloma Network
Meletios A. Dimopoulos, Ramón García Sanz, Maria Gavriatopoulou, Pierre Morel, Marie-Christine Kyrtsonis, Eirini Katodritou,
Eurydiki Michalis, Zafiris Kartasis, Xavier Leleu, Giovanni Palladini, Alessandra Tedeschi, Dimitra Gika, Evangelos Terpos,
Giampaolo Merlini, Efstathios Kastritis, and Pieter Sonneveld
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1941
Poster Board: I-921
Prospective Canadian Trial In Newly Diagnosed Multiple Myeloma Patients with t(4;14):
Bortezomib-Based Therapy without ASCT
Donna E. Reece, Giovanni Piza Rodriguez, Andrew Belch, David Szwajcer, Michael J. Kovacs, Chaim Shustik, Nizar J Bahlis,
Darrell J White, Mariela Pantoja, Christine Chen, Vishal Kukreti, Peter Anglin, and Suzanne Trudel
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1968
Poster Board: I-948
The Proteasome Inhibitor Bortezomib Stimulates Osteoblastic Differentiation of Human Osteoblast Precursor Cells
Via Upregulation of Vitamin D Receptor Signaling
Martin Kaiser, Maren Mieth, Orhan Sezer and Ulrike Heider
Poster Session: Myeloma - Biology and Pathophysiology, excluding Therapy: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1899
Poster Board: I-879
www.myeloma.org
(800) 452 - CURE (2873)
Response to Induction Chemotherapy with Novel Agents Does Not Predict Outcomes of Multiple Myeloma Patients
Undergoing Autologous Hematopoietic Cell Transplantation
Salman Osman, Abraham Sebastian Kanate, Pamela Bunner, Sonia Leadmon, William Tse, Aaron Cumpston, Laura Gibson,
Scot Remick, Jame Abraham, Michael Craig, and Sayed Mehdi Hamadani
Poster Session: Clinical Results - Autologous Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1347
Poster Board: I-327
Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib
In Patients with Relapsed/Refractory Multiple Myeloma
Peter M Voorhees, Cristina Gasparetto, Keren Osman, Kristy Richards, Madlyn Ferraro, Reynaldo Garcia, Jennifer MacLean,
Diane Winans, Dominic Moore, John Strader, Robert Z. Orlowski, and David Duane Hurd
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1955
Poster Board: I-935
Smoldering Multiple Myeloma (SMM) at High-Risk of Progression to Symptomatic Disease:
A Phase III, Randomized, Multicenter Trial Based On Lenalidomide-Dexamethasone (Len-Dex) as Induction Therapy
Followed by Maintenance Therapy with Len Alone Vs No Treatment
María Victoria Mateos, Lucía López Corral, Miguel Hernández, Pilar Giraldo, Javier de la Rubia, Felipe de Arriba, Laura Rosiñol,
Juan-José Lahuerta, Luis Palomera, Joan Bargay, Albert Oriol, Felipe Prosper, Jose García Laraña, Eduardo Olavarría,
Maria Luz Martino, Ana Isabel Teruel, José Hernández, Graça Esteves, José Mario Mariz, Fernando Leal-da-Costa, Adrian Alegre,
José-Luis Guzman, Ana López de la Guía, Nuria Quintana, José Baquero, José Luis García and Jesús F. San Miguel
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1935
Poster Board: I-915
Thromboprophylaxis In Multiple Myeloma Patients Undergoing Immunomodulatory Therapy with Thalidomide and
Lenalidomide: A Systematic Review and Meta-Analysis
Marc Carrier, Gregoire Le Gal, Jason Tay, Cynthia M. Wu, and Agnes Y. Lee
Poster Session: Antithrombotic Therapy: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1090
Poster Board: I-70
Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T),
Dexamethasone (D) and Interferon (I) Maintenance Components
Frits van Rhee, Bart Barlogie, Jackie Szymonifka, Elias J. Anaissie, Bijay Nair, Sarah Waheed, Yazan Alsayed, Nathan Petty,
John Shaughnessy Jr., Antje Hoering, and John Crowley
Poster Session: Clinical Results - Autologous Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1356
Poster Board: I-336
Upfront Treatment with Novel Agents Improves the Survival of Symptomatic Patients with Multiple Myeloma
Who Are Older Than 65 Years
Meletios A. Dimopoulos, Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Maria Gkotzamanidou,
Agapi Parcharidou, Dimitra Gika, and Evangelos Terpos
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1947
Poster Board: I-927
www.myeloma.org
(800) 452 - CURE (2873)
Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma:
Update on the Vantage Study Program
David S. Siegel, Sundar Jagannath, Roman Hájek, Meletios A. Dimopoulos, Sung-Soo Yoon, Sagar Lonial, Jacob P. Laubach,
Thorsten Graef, Dina Pietrangelo, Lisa Lupinacci, David Reiser, and Kenneth C. Anderson
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster I
Time: 5:30 PM-7:30 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 1952
Poster Board: I-932
Sunday, December 5th
Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous
Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104
Philip L. McCarthy, Kouros Owzar, Kenneth C. Anderson, Craig C. Hofmeister, David Duane Hurd, Hani Hassoun, Sergio Giralt,
Edward A. Stadtmauer, Paul G Richardson, Daniel J. Weisdorf, Ravi Vij, Jan S Moreb, Natalie Scott Callander, Koen Van Besien,
Teresa Gentile, Luis Isola, Richard T. Maziarz, Don A. Gabriel, Asad Bashey, Heather Landau, Thomas Martin, Muzaffar H. Qazilbash,
Denise Levitan, Brian McClune, Vera Hars, John Postiglione, Chen Jiang, Elizabeth Bennett, Susan S. Barry, Linda Bressler,
Michael Kelly, Michele Sexton, Cara Rosenbaum, Hari Parameswaran, Marcelo C Pasquini, Mary M. Horowitz, Thomas C. Shea,
Steven M. Devine, and Charles Linker
Oral Session: Clinical Results - Autologous Transplantation: Multiple Myeloma
Time: 4:30 PM
Location: 109A (Orange County Convention Center)
Abstract No.: 37
Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation
In the ECOG E4A03 Randomized Clinical Trial
David Siegel, Susanna Jacobus, S. Vincent Rajkumar, Rafat Abonour, Natalie Scott Callander, Michael S. Katz, Rafael Fonseca,
David H. Vesole, and on behalf of the Eastern Cooperative Oncology Group
Oral Session: Clinical Results - Autologous Transplantation: Multiple Myeloma
Time: 4:45 PM
Location: 109A (Orange County Convention Center)
Abstract No.: 38
A Randomized Phase III Trial of Thalidomide and Prednisone as Maintenance Therapy Following Autologous Stem Cell
Transplantation (ASCT) In Patients with Multiple Myeloma (MM): The NCIC CTG MY.10 Trial
A. Keith Stewart, Suzanne Trudel, Nizar J. Bahlis, Darrell J. White, Waleed Sabry, Andrew Belch, Tony Reiman, Jean Roy, Chaim Shustik,
Michael J. Kovacs, Jonathan Sussman, Ralph M. Meyer, Erica L Harnett, Danila Oana, Judy A. Chapman, and Lois Shepherd
Oral Session: Clinical Results - Autologous Transplantation: Multiple Myeloma
Time: 5:00 PM
Location: 109A (Orange County Convention Center)
Abstract No.: 39
HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD
Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly
Diagnosed Multiple Myeloma (MM)
Pieter Sonneveld, Ingo Schmidt-Wolf, Bronno van der Holt, Laila el Jarari, Uta Bertsch, Hans Salwender, Sonja Zweegman,
Edo Vellenga, Joerg Schubert, Igor Wolfgang Blau, Asiong Jie, Berna Beverloo, Dirk Hose, Anna Jauch, Helgi van de Velde,
Martijn Schaafsma, Walter Lindemann, Marie Jose Kersten, Ulrich Duehrsen, Michel Delforge, Katja Weisel, Sandra Croockewit,
Hans Martin, Shulamit Wittebol, Christof Scheid, Gerard Bos, Marinus van Marwijk-Kooy, Pierre Wijermans, Henk Lokhorst,
and Hartmut Goldschmidt
Oral Session: Clinical Results - Autologous Transplantation: Multiple Myeloma
Time: 5:15 PM
Location: 109A (Orange County Convention Center)
Abstract No.: 40
www.myeloma.org
(800) 452 - CURE (2873)
MELISSE, a Large Multicentric Observational Study to Determine Criteria and Risk Factors of Thromboembolism for Patients
with Multiple Myeloma Treated with Immunomodulator Drugs
Xavier Leleu, Laurent Daley, Philippe Rodon, Cyrille Hulin, Ahmad AL Jijakli, Olivier Fitoussi, Charles Dauriac, Bruno Lioure,
Laurent Voillat, Borhane Slama, Maya Hacini, Régis Costello, Jean Claude Eisenmann, Carine Chaleteix, Olivier Decaux,
Anne Lamblin, Patrick Natta, Jean Paul Fermand, and Philippe Moreau
Oral Session: Pathophysiology of Thrombosis: Population Based Studies
Time: 5:30 PM
Location: Hall F5 (Orange County Convention Center)
Abstract No.: 809
Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and
Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma:
Results From a Randomized Phase III Study
Michele Cavo, Giulia Perrone, Silvia Buttignol, Elisabetta Calabrese, Monica Galli, Sara Bringhen, Tonino Spadano, Luca Baldini,
Tommaso Caravita, Chiara Nozzoli, Annamaria Brioli, Luciano Masini, Anna Furlan, Lucia Pantani, Daniele Derudas,
Stelvio Ballanti, Francesco Pisani, Valerio De Stefano, Gioacchino Catania, Luca Castagna, Felicetto Ferrara, Vincenzo Callea,
Pellegrino Musto, Elena Zamagni, and Michele Baccarani
Oral Session: Clinical Results - Autologous Transplantation: Multiple Myeloma
Time: 5:45 PM
Location: 109A (Orange County Convention Center)
Abstract No.: 42
AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3
In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity
Loredana Santo, Teru Hideshima, Diana Cirstea, Madhavi L. Bandi, Erik A. Nelson, Hiroshi Ikeda, Sonia Vallet, Samantha Pozzi,
Kishan Patel, Gullu Gorgun, Naoya Mimura, Claire Fabre, Yiguo Hu, Dharminder Chauhan, Matthew S. Squires, Nikhil C. Munshi,
Kenneth C. Anderson, and Noopur Raje
Poster Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2994
Poster Board: II-874
Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients
with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation
Laurent Garderet, Simona Iacobelli, Philippe Moreau, Mamoun Dib, Denis Caillot, Dietger W. Niederwieser, Tamas Masszi,
Jean Fontan, Mauricette Michallet, Alois Gratwohl, Giuseppe Milone, Chantal Doyen, Brigitte Pegourie, Roman Hájek,
Philippe Casassus, Brigitte Kolb, Carine Chaleteix, Bernd Hertenstein, Francesco Onida, Heinz Ludwig, Marie Christiane Vekemans,
Nicolas Ketterer, Anne Daguenel, Norbert C. Gorin, Jean Luc Harousseau, Theo de Witte, Curly Morris, and Gösta Gahrton
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3043
Poster Board: II-923
BT062, a CD138-Specific Immunoconjugate, Demonstrates Superior In Vivo Anti-Myeloma Efficacy
In Combination with Lenalidomide or Bortezomib
Chantal Zuber, Benjamin Daelken, Silke Aigner, Thomas Haeder, Olga Ab, Kathleen Whiteman, Teru Hideshima, Robert J Lutz,
Frank Osterroth, and Christoph Uherek
Poster Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3008
Poster Board: II-888
Circulating Levels of the Wnt Inhibitors Dickkopf-1 and Sclerostin In Different Phases of Multiple Myeloma:
Alterations Post-Therapy with Lenalidomide and Dexamethasone with or without Bortezomib
Evangelos Terpos, Dimitrios Christoulas, Maria Gkotzamanidou, Cornelia Bratengeier, Maria Gavriatopoulou, Magdalini Migkou,
Athanasios Papatheodorou, Efstathios Kastritis, Wolfgang Woloszczuk, and Meletios A. Dimopoulos
Poster Session: Myeloma - Biology and Pathophysiology, excluding Therapy: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2963
Poster Board: II-843
www.myeloma.org
(800) 452 - CURE (2873)
The Combination of Cyclophosphamide-Bortezomib-Dexamethasone (CYBOR-D) Is a Highly Effective and
Well Tolerated Regimen that Produces Rapid and Complete Hematological Response In Patients with AL Amyloidosis
Joseph R. Mikhael, Steven R. Schuster, Victor H. Jimenez-Zepeda, Nancy Bello, Jacy Spong, Craig B. Reeder, A. Keith Stewart,
P.Leif Bergsagel, and Rafael Fonseca
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3063
Poster Board: II-943
The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD Regimen)
as Front-Line Therapy In Newly Diagnosed, High-Risk Multiple Myeloma: Results of a Phase II Prospective Multicenter Study
Ioannis Baltathakis, Evangelos Terpos, Sosana Delimpasi, Konstantinos Liapis, Fotios Panitsas, Efstathios Kastritis,
Anna Christoforidou, Anastasia Pouli, Konstantinos Tsatalas, Meletios A. Dimopoulos, and Nikolaos Harhalakis
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3052
Poster Board: II-932
A Comparison of Chemotherapy + G-CSF Versus Plerixafor (Mozobil®) + G-CSF for Stem Cell Mobilization
In Patients with Multiple Myeloma Treated with Lenalidomide
Tomer M. Mark, Adriana C. Rossi, Roger N. Pearse, Morton Coleman, David Bernstein, Faiza Zafar, Usama Gergis, Tsiporah B. Shore,
and Ruben Niesvizky
Poster Session: Cell Processing: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2258
Poster Board: II-138
Consolidation with Bortezomib, Thalidomide and Dexamethasone After High Dose Therapy Is Feasible, Safe and Effective
In De Novo Multiple Myeloma Patients Who Already Received New Drugs Containing-Induction Regimen
Murielle Roussel, Gaëlle Dörr, Willy Vaillant, Anne Huynh, and Michel Attal
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3041
Poster Board: II-921
The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone
with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States
Si-Tien Wang, Hui Huang, Abbie Ba-Mancini, Hongliang Shi, Kristina Chen, Caroline Korves, Ravinder Dhawan, Andrew Cakana,
Helgi van de Velde, Dixie-Lee W. Esseltine, and Mei S. Duh
Poster Session: Health Services and Outcomes Research: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2563
Poster Board: II-443
Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional
and Novel Anti-Myeloma Drugs
Sun-Young Kong, Xian-Feng Li, Sabikun Nahar, Weihua Song, Michel de Weers, Paul W.H.I. Parren, Paul Richardson, Nikhil C. Munshi,
Kenneth C. Anderson, and Yu-Tzu Tai
Poster Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3013
Poster Board: II-893
Dose Finding Study of Lenalidomide as Maintenance Therapy In Multiple Myeloma After Allogeneic Stem Cell Transplantation
Christine Wolschke, Stefan O. Schonland, Ute Hegenbart, Thomas Stübig, Marion Heinzelmann, York Hildebrandt, Michael Lioznov,
Axel R. Zander, and Nicolaus Kröger
Poster Session: Clinical Results - Alternative Donor Transplantation: Poster I
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2376
Poster Board: II-256
www.myeloma.org
(800) 452 - CURE (2873)
Effect of Novel Agents on Stem Cell (SC) Mobilization and Engraftment In Patients with Multiple Myeloma (MM)
at Memorial Sloan-Kettering Cancer Center
Melissa Pozotrigo, Nelly G. Adel, Vincent LaRussa, Xiaoshe Chen, Elyn Riedel, Lilian Reich, Heather Landau, Sergio Giralt,
and Hani Hassoun
Poster Session: Cell Processing: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2262
Poster Board: II-142
Effect of Thalidomide with Melphalan and Prednisone on Health-Related Quality of Life (HRQoL) in Elderly Patients
with Newly Diagnosed Multiple Myeloma: A Prospective Analysis In a Randomized Trial
S. Verelst, F. Termorshuizen, C. Uyl-de Groot, M. R Schaafsma, R. Ammerlaan, S. Wittebol, H. Sinnige, S. Zweegman,
M. van Marwijk Kooy, R. van der Griend, H. Lokhorst, P. Sonneveld and P. Wijermans
Poster Session: Myeloma - Biology and Pathophysiology, excluding Therapy: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2972
Poster Board: II-852
Effective Primary Mobilization of Autologous Peripheral Blood Stem Cells with Granulocyte Colony-Stimulating Factor
and Plerixafor in Lenalidomide-Treated Patients with Multiple Myeloma
Faiz Anwer, Myke R. Green, and Andrew M. Yeager
Poster Session: Cell Processing: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2254
Poster Board: II-134
Efficacy and Safety of Once Weekly Bortezomib In Multiple Myeloma Patients
Sara Bringhen, Alessandra Larocca, Davide Rossi, Alessandra Romano, Mariella Genuardi, Roberto Ria, Pietro Leoni,
Francesca Patriarca, Chiara Nozzoli, Tommasina Guglielmelli, Giulia Benevolo, Vincenzo Callea, Fabiana Gentilini, Francesca Elice,
Barbara Olivero, Mariella Grasso, Antonietta Pia Falcone, Daniela Gottardi, Vittorio Montefusco, Alessandro Allegra, Manuela Rizzo,
Giovanna Leonardi, Daniela Oddolo, Fortunato Morabito, Mario Boccadoro, and Antonio Palumbo
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3029
Poster Board: II-909
Efficacy of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients with Relapsed/Refractory
Multiple Myeloma: An Interim Report from an International Electronic Observational Study
Meletios A. Dimopoulos, Hadewijch M. De Samblanx, Maria G. Roussou, Konstantinos Zervas, Eirini Katodritou, Deniz Sargin,
Cyrille Hulin, Lucia Ahlberg, Javier de la Rubia, Rita Ganguly, Joris K Diels, Helgi van de Velde, Ravinder Dhawan,
Michael D. Spencer, and Michel Delforge
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3027
Poster Board: II-907
Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma:
Updated Results of a Phase I Study
Andrzej J. Jakubowiak, Don M. Benson Jr., William Bensinger, David S. Siegel, Todd M. Zimmerman, Ann Mohrbacher,
Paul G. Richardson, Daniel E.H. Afar, Anil K. Singhal, and Kenneth C. Anderson
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3023
Poster Board: II-903
www.myeloma.org
(800) 452 - CURE (2873)
Final Phase I Results of Perifosine In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed
or Refractory Multiple Myeloma (MM)
Andrzej J. Jakubowiak, Paul G. Richardson, Todd M. Zimmerman, Melissa Alsina, Jonathan L. Kaufman, Malathi Kandarpa,
Colleen K. Harvey, Kathleen Colson, Monica Mitchell, Teru Hideshima, Peter Sportelli, Lesa Gardner, Kathy Giusti,
and Kenneth C. Anderson
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3064
Poster Board: II-944
Fotemustine In Combination With Bortezomib And Dexamethasone:
Encouraging Preliminary Results From A Phase II Study On Relapsed Refractory Myeloma Patients
Alessandro Corso, Silvia Mangiacavalli, Federica Cocito, Cristiana Pascutto, Cesare Astori, Marzia Varettoni, Ester Orlandi,
Patrizia Zappasodi, Silvia Rizzi, Ilaria Ambaglio, Mario Lazzarino, and Mario Cazzola
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3037
Poster Board: II-917
Geographic and Racial Disparities In Multiple Myeloma Outcomes In the USA
Shahrukh Hashmi, Chris Mooney, Gordon L. Phillips II, Jane L. Liesveld, and Jainulabdeen J. Ifthikharuddin
Poster Session: Health Services and Outcomes Research: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2557
Poster Board: II-437
High Rate of Complete Remission (CR) and Upgraded Response with Weekly Maintenance Bortezomib Post Single Autologous
Peripheral Stem Cell Transplant (PSCT) In Patients with Multiple Myeloma. Results of a Phase II Prospective Study
Firoozeh Sahebi, Amrita Krishnan, Leonardo Farol, Ji-Lian Cai, George Somlo, Leslie Popplewell, R. Spielberger, Neil Martin Kogut,
Chatchada Karanes, Christopher Ruel, Paul Frankel, Eunicia Reburiano, Margret O'Donnell, and Stephen Forman
Poster Session: Clinical Results - Autologous Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2399
Poster Board: II-279
High Resolution Genome-Wide Analyses Revealed That Bortezomib Selects a Prediagnosis Clone In Relapsed Patients
with Multiple Myeloma
Florence Magrangeas, Hervé Avet-Loiseau, Olivier Decaux, Wilfried Gouraud, Jean Luc Harousseau, Kenneth C. Anderson,
Philippe Moreau, Nikhil C. Munshi, and Stephane Minvielle
Poster Session: Myeloma - Biology and Pathophysiology, excluding Therapy: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2960
Poster Board: II-840
Improved Myeloma Targeting by Combination of the Human Anti-CD38 Antibody Daratumumab
with Lenalidomide and Bortezomib
Michael S. van der Veer, Michel de Weers, Berris van Kessel, Joost M. Bakker, Shulamiet Wittebol, Paul W.H.I. Parren, Henk M. Lokhorst,
and Tuna Mutis
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3030
Poster Board: II-910
Incorporation of Bortezomib Into Frontline Treatment of Multiple Myeloma According to Risk Stratification Shifts
the Most Significant Prognostic Indicator From Cytogenetics to the Quality of Induction Response
Daryl Tan, Bernard K.C. Yap, Lionel K.Y See, Grace Kam, Colin Phipps Diong, Yuh Shan Lee, Dawn Mya, William Hwang,
and Yeow Tee Goh
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3056
Poster Board: II-936
www.myeloma.org
(800) 452 - CURE (2873)
Increases In B-Type Natriuretic Peptide (BNP) During Treatment with Lenalidomide In AL Amyloidosis
Umit Tapan, David C. Seldin, Kathleen T. Finn, Salli Fennessey, Anthony C. Shelton, Jerome B. Zeldis, and Vaishali Sanchorawala
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3021
Poster Board: II-901
Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment
Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial
for Newly Diagnosed Multiple Myeloma
Christof Scheid, Pieter Sonneveld, Ingo Schmidt-Wolf, Bronno van der Holt, Thomas Hielscher, Laila el Jarari, Uta Bertsch,
Hans Salwender, Sonja Zweegman, Mathias Hänel, Edo Vellenga, Joerg Schubert, Igor Wolfgang Blau, Asiong Jie, Helgi van de Velde,
Norma Peter, Martijn Schaafsma, Walter Lindemann, Marie Jose Kersten, Ulrich Duehrsen, Michel Delforge, Katja Weisel,
Sandra Croockewit, Hans Martin, Shulamit Wittebol, Harry Schouten, Marinus van Marwijk-Kooy, Pierre Wijermans,
Henk M. Lokhorst, and Hartmut Goldschmidt
Poster Session: Clinical Results - Autologous Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2396
Poster Board: II-276
Interim Results of An Ongoing Clinical Study Suggests Efficacy and Improved Toxicity Profile with Once a Week Bortezomib
with Dexamethasone In Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities
Nikhil C. Munshi, Saem Lee, Suman Kambhampati, Abid Mohiuddin, Michal Rose, Caroline Behler, Andrew Han, Yvonne Efebera,
Antoun Houranieh, Mary T. Brophy, Abraham Zimelman, Rao H Prabhala, Hussain I. Saba, Catherine Klein, Paulette Mehta,
Teresa Hayes, David Roodman, and Alan K. Lichtenstein
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3061
Poster Board: II-941
Lenalidomide, Bortezomib, and Dexamethasone (RVD) In Combination with Vorinostat as Front-Line Therapy
for Patients with Multiple Myeloma (MM): Initial Results of a Phase 1 Study
Jonathan L. Kaufman, Jatin J. Shah, Jacob P. Laubach, Leonard Heffner, Dixil Francis, R. Donald Harvey, Colleen Lewis,
Mourad Tighiouart, Paul Richardson, Robert Z. Orlowski, and Sagar Lonial
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3034
Poster Board: II-914
Lenalidomide In Combination with Zoledronic Acid Restores the Activation and Anti-Myeloma Effects
of T Cells Attenuated by the Bone Marrow Microenvironment
Qu Cui, Masahiro Abe, Hirokazu Miki, Shingen Nakamura, Keiichiro Watanabe, Akishige Ikegame, Masahiro Hiasa, Ayako Nakano,
Takeshi Harada, Shiro Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, and Toshio Matsumoto
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3025
Poster Board: II-905
Lenalidomide Treatment In Patients with AL Amyloidosis Associated End-Stage Renal Disease and Dialysis
Vaishali Sanchorawala, Kathleen T. Finn, Salli Fennessey, Anthony C. Shelton, Jerome B. Zeldis, and David C. Seldin
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3022
Poster Board: II-902
www.myeloma.org
(800) 452 - CURE (2873)
Long Term Follow up of the Combination of Bortezomib with Dexamethasone as Initial Treatment for AL Amyloidosis
Efstathios Kastritis, Maria Roussou, Magdalini Migkou, Maria Gavriatopoulou, Constantinos Pamboukas, Sosana Delimpassi,
Evelina Charitaki, Eurydiki Michalis, Kaladaridou Anna, Plastiras Sotirios, Dimitrios Gogos, Agrios Ioannis, Evangelos Terpos,
and Meletios A. Dimopoulos
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3048
Poster Board: II-928
Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant
In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy
Heather Landau, Hani Hassoun, Michael A. Rosenzweig, Christina Bello, Elizabeth Hoover, Elyn Riedel, Alex Lesokhin,
Nikoletta Lendvai, Adam Cohen, Stephen Nimer and Raymond L. Comenzo
Poster Session: Clinical Results - Autologous Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2391
Poster Board: II-271
Melphalan, Thalidomide and Prednisone (MPT) Combined with Oral Panobinostat In Patients with Relapsed/Refractory MM:
a Phase I-II Study
Massimo Offidani, Federica Cavallo, Claudia Polloni, Anna Marina Liberati, Stelvio Ballanti, Stefano Pulini, Massimo Catarini,
Francesco Alesiani, Laura Corvatta, Silvia Gentili, Mario Boccadoro, Pietro Leoni, and Antonio Palumbo
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3019
Poster Board: II-899
Novel Thrombogenic Biomarkers In Patients with Relapsed/Refractory Multiple Myeloma (MM) Treated
with Lenalidomide (LEN) and Dexamethasone (Dex) Therapy
Kate Burbury, Peter C. Gambell, Amanda Choo, Jennifer Curnow, Kevin Lynch, Simon J. Harrison, Hang Quach, David Ritchie,
Miles Prince, and David Alan A. Westerman
Poster Session: Pathophysiology of Thrombosis: Poster I
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3187
Poster Board: II-1067
Oligoclonal Bands In Patients with Multiple Myeloma In Complete Remission After Induction Chemotherapy:
Strong Association with the Use of Novel Agents
Carlos Fernández de Larrea, Natalia Tovar, María Teresa Cibeira, Juan I. Aróstegui, Laura Rosiñol, Montserrat Elena, Xavier Filella,
Jordi Yagüe, and Joan Blade
Poster Session: Myeloma - Biology and Pathophysiology, excluding Therapy: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2945
Poster Board: II-825
An Open-Label Phase I/II Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory
Multiple Myeloma
James R. Berenson, Ori Yellin, Alberto Bessudo, Ralph Boccia, Donald S. Gravenor, Stephen J. Noga, Robert S. Siegel, Regina A. Swift,
Michael D. Ehrman, and Debra Bensen-Kennedy
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3057
Poster Board: II-937
Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach
Bart Heeg, Michel van Agthoven, Johan Liwing, Ulf-Henrik Mellqvist, Torben Plesner, Floris Logman, Verena Donatz, Johan Aschan,
Hermann Einsele, Martin Kropff, Maarten Treur, Mirjam Barendse, Jean-Luc Harousseau, Antonio Palumbo, and Pieter Sonneveld
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3046
Poster Board: II-926
www.myeloma.org
(800) 452 - CURE (2873)
Patient-Reported Quality of Life In Elderly, Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based
Regimens: Results From the Phase IIIb UPFRONT Study
Ruben Niesvizky, Ian W. Flinn, Robert M. Rifkin, Nashat Y. Gabrail, Veena Charu, Billy Clowney, James Essell, Yousuf A. Gaffar,
Thomas A. Warr, Rachel Neuwirth, Deyanira Corzo, and James A. Reeves
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3026
Poster Board: II-906
Peripheral Blood Stem Cell Collection In Patients Undergoing Induction Therapy with Lenalidomide Based Regimens:
Failure Rates and Salvage Approaches
Shirshendu Sinha, Morie Gertz, Martha Lacy, Angela Dispenzieri, Suzanne Hayman, Francis Buadi, David Dingli, Ivana Micallef,
William Hogan, Dennis Gastineau, Vincent Rajkumar, and Shaji Kumar
Poster Session: Cell Processing: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2253
Poster Board: II-133
Pharmacological Study of Antimyeloma Agents on Hemostasis
François Mullier, Severine Robert, Philippe Devel, Lutfiye Alpan, Nicolas Lufin, Bernard Chatelain, and Jean-Michel Dogné
Poster Session: Pathophysiology of Thrombosis: Poster I
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3175
Poster Board: II-1055
Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment
of Patients with Relapsed and Refractory Multiple Myeloma
Donna E. Reece, Esther Masih-Khan, Arooj Khan, Saima Dean, Sharon Fung, Peter Anglin, Christine Chen, Vishal Kukreti,
Joseph R. Mikhael, and Suzanne Trudel
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3055
Poster Board: II-935
A Phase I Study of Bortezomib During Maintenance Phase After High-Dose Melphalan and Autologous Stem Cell
Transplantation In Patients with Multiple Myeloma
Muneer H. Abidi, Zartash Gul, Lawrence G. Lum, Judith Abrams, Simon Cronin, Marie Ventimiglia, Abhinav Deol, Lois Ayash,
Zaid Al-Kadhimi, Voravit Ratanatharathorn, and Joseph P. Uberti
Poster Session: Clinical Results - Autologous Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2387
Poster Board: II-267
A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R)
for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM)
James R. Berenson, Ori Yellin, Alan D. Cartmell, Thomas B. S. Woliver, Marshall S. Flam, Youram Nassir, Robert Vescio,
and Regina A. Swift
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3044
Poster Board: II-924
Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and
Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up
Paul G. Richardson, Sundar Jagannath, Andrzej J. Jakubowiak, Sagar Lonial, Noopur Raje, Melissa Alsina, Irene Ghobrial,
Robert L. Schlossman, Amitabha Mazumder, Nikhil C. Munshi, David H. Vesole, Kathleen Colson, Mary L McKenney, Laura E. Lunde,
John Feather, Teru Hideshima, Robert D. Knight, Dixie-Lee Esseltine, Constantine S. Mitsiades, and Kenneth C. Anderson
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3049
Poster Board: II-929
www.myeloma.org
(800) 452 - CURE (2873)
A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone
In Patients with Early Stage Multiple Myeloma (MC0289)
Thomas E. Witzig, Sumithra Mandrekar, Kristen Detweiler-Short, Martha Q. Lacy, Kristina Laumann, Angela Dispenzieri,
Suzanne R. Hayman, Shaji Kumar, Craig B. Reeder, Vivek Roy, John A. Lust, Morie A. Gertz, Philip R. Greipp, and S. Vincent Rajkumar
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3053
Poster Board: II-933
Renal Impairment Is Not An Independent Adverse Prognostic Factor In Multiple Myeloma Patients
Who Are Treated Upfront with Novel Agent-Based Regimens
Meletios A. Dimopoulos, Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Maria Gkotzamanidou,
Marina Iakovaki, Charis Matsouka, Despina Mparmparousi, Nikitas Nikitas, Dimitra Gika, Irene Grapsa, Erasmia Psimenou,
and Evangelos Terpos
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3033
Poster Board: II-913
Safety, Efficacy, and Quality-of-Life Study of Lenalidomide Plus Dexamethasone In Previously Treated Patients
with Multiple Myeloma: The Spanish Experience
Adrian Alegre, Albert Oriol Rocafiguera, Jose García Laraña, María Victoria Mateos, Anna Sureda, Carmen Martínez Chamorro,
María Teresa Cibeira, Robert Knight, and Barbara Rosettani
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3045
Poster Board: II-925
Salvage Therapy with Lenalidomide and Dexamethasone (LDex) In Patients with Advanced AL Amyloidosis Refractory
to Both Melphalan and Bortezomib
Giovanni Palladini, Paola Russo, Paolo Milani, Andrea Foli, Letizia Zenone Bragotti, Laura Obici, Francesca Lavatelli,
Silvia Brugnatelli, Vittorio Perfetti, Rosangela Invernizzi, and Giampaolo Merlini
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3062
Poster Board: II-942
Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance
In Multiple Myeloma (MM)
Loredana Santo, Teru Hideshima, Andrew L. Kung, Matthew Jarpe, Diana Cirstea, Kishan Patel, Samantha Pozzi, Jen C. Tseng,
Scott J. Rodig, James Bradner, Kenneth C. Anderson, Simon Jones, and Noopur Raje
Poster Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 2997
Poster Board: II-877
Short Progression Free Survival Predicts for Poor Overall Survival In Older Patients with Multiple Myeloma Treated Upfront
with Novel Agent-Based Therapy
Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Magdalini Migkou, Maria Gkotzamanidou, Marina Iakovaki,
Eleni Efstathiou, Evangelos Terpos, and Meletios A. Dimopoulos
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3035
Poster Board: II-915
www.myeloma.org
(800) 452 - CURE (2873)
Thalidomide, Dexamethasone, Doxil and Velcade (ThaDD-V) Induction Therapy Followed by Consolidation/Maintenance
Is Very Effective In Early Relapsed/Refractory MM
Massimo Offidani, Claudia Polloni, Laura Corvatta, Silvia Gentili, Anna Mele, Marino Brunori, Rita Rizzi, Massimo Catarini,
Arduino Samori, Nicola Blasi, Mario Ferranti, Lara Malerba, Patrizia Caraffa, and Pietro Leoni
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3020
Poster Board: II-900
Towards Effective Immunotherapy of Multiple Myeloma: Enhanced Elimination of Myeloma Cells by Combination
of Lenalidomide with the Human CD38 Monoclonal Antibody Daratumumab
Michael S. van der Veer, Michel de Weers, Berris van Kessel, Shulamiet Wittebol, Joost M. Bakker, Paul W.H.I. Parren, Henk M. Lokhorst,
and Tuna Mutis
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3059
Poster Board: II-939
Updated Report of T-Bird (thalidomide, clarithromycin/[Biaxin®], lenalidomide/[Revlimid®], Dexamethasone) Therapy
for Upfront Use In Symptomatic Multiple Myeloma
Tomer M. Mark, Jennifer O'Loughlin, Morton Coleman, David Jayabalan, Roger N. Pearse, Faiza Zafar, Scott A. Ely, Megan Manco,
Patrice Mignott, John P. Leonard, Selina Chen-Kiang, and Ruben Niesvizky
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3050
Poster Board: II-930
Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory
Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis
Anuj Mahindra, Paul G. Richardson, Parameswaran Hari, Aliyah R. Sohani, Jacob P. Laubach, Jill Burke, Sarah Kaster,
Christine Connolly, Linda Rivera, Paulette Jacobs, Ayman Saad, Kathleen Colson, Irene Ghobrial, Robert L. Schlossman,
Jennifer Adams, Wendy Makrides, Edie Weller, Nikhil C. Munshi, Kenneth C. Anderson, and Noopur Raje
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3051
Poster Board: II-931
Updated Results of the Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Low Dose Dexamethasone (DEX) and
Lenalidomide (LEN) In Patients with Newly Diagnosed (ND) Multiple Myeloma (MM)
Rachid Baz, Mohamad A. Hussein, Daniel Sullivan, Jose-Leonel Ochoa-Bayona, Monique A. Hartley, Kenneth Shain, Taiga Nishihori,
Jennifer Paleveda, Kara Kosakowski, William S. Dalton, and Melissa Alsina
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3054
Poster Board: II-934
Use of Lenalidomide May Surmount the Adverse Prognosis Induced by Renal Impairment In Patients (pts)
with Relapsed/Refractory Multiple Myeloma (MM)
Martina Kleber, Gabriele Ihorst, Josefina Udi, Bernd Koch, and Monika Engelhardt
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3042
Poster Board: II-922
The Vk*MYC Mouse Model of Myeloma Identifies Successful Combination Therapies for the Treatment of Bortezomib
Refractory Myeloma Patients
Marta Chesi, Stephen Palmer, Victoria Garbitt, and P. Leif Bergsagel
Poster Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3015
Poster Board: II-895
www.myeloma.org
(800) 452 - CURE (2873)
Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance
In Relapsed/Refractory Multiple Myeloma
David Samuel diCapua Siegel, Laura McBride, Elizabeth Bilotti, Linda Schmidt, Zhijie Gao, Madiha Tufail, Nikoletta Lendvai,
Ann McNeill, Kristen Donadio, Karly Olivo, Urzula Bednarz, Thorsten Graef, and David H. Vesole
Poster Session: Myeloma - Therapy, excluding Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3065
Poster Board: II-945
Zalypsis Has Synergistic Effect When Combined with Bortezomib + Dexamethasone through Caspase Dependent
and Mainly Independent Mechanisms and through A Potent Induction of DNA Damage
Enrique M. Ocio, Lorena González Coco, Laura San-Segundo, Xi Chen, Teresa Hernández Iglesias, Diego Fernández Lázaro,
Teresa Paíno, Mercedes Garayoa, Carmen Cuevas, Pablo Avilés, Enrique Álava, Atanasio Pandiella, and J.F. San Miguel
Poster Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3003
Poster Board: II-883
Monday, December 6th
A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple
Myeloma: Superiority of VTD (Bortezomib/ Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib
Laura Rosiñol, María Teresa Cibeira, Maria Victoria Mateos, Joaquin Martinez, Albert Oriol, Ana Isabel Teruel, Dolores Hernández,
José García Laraña, Javier de la Rubia, Anna Sureda, Juan Besalduch, Luis Palomera, Yolanda González, Maria Asunción Etxebeste,
Joaquín Díaz Mediavilla, Miguel T. Hernández, Felipe de Arriba, Adrian Alegre, Juan José Lahuerta, Jesus F. San Miguel,
and Joan Blade
Oral Session: Myeloma - Therapy, excluding Transplantation: Randomized Trials
Time: 7:00 AM
Location: Auditorium-320 (Orange County Convention Center)
Abstract No.: 307
Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to
Lenalidomide Plus High-Dose Dexamethasone (LD)
David H. Vesole, Susanna Jacobus, S. Vincent Rajkumar, Rafat Abonour, Natalie Scott Callander, Philip R. Greipp, Rafael Fonseca,
Michael S. Katz, David S. Siegel, and On Behalf of the Eastern Cooperative Oncology Group
Oral Session: Myeloma - Therapy, excluding Transplantation: Randomized Trials
Time: 7:15 AM
Location: Auditorium-320 (Orange County Convention Center)
Abstract No.: 308
Clinical Outcome According to Both Cytogenetic Abnormalities (CA) Detected by Fluorescence In Situ Hibridization (FISH)
and Hyperdiploidy Assessed by Flow Cytometry (FCM) In Elderly Newly Diagnosed Myeloma Patients Treated
with A Bortezomib-Based Combination
María Victoria Mateos, Norma C. Gutierrez, Bruno Paiva, Albert Oriol, Joaquín Martínez López, Ana Isabel Teruel, Raquel de Paz,
Jose Garcia Laraña, Enrique Bengoechea, Alejandro Martín, Joaquín Díaz Mediavilla, Luis Palomera, Yolanda Gonzalez,
Jose Mariano Hernández, Ana Sureda, Jose Luis Bello, Joan Bargay, Francisco Javier Penalver, Josep Maria Ribera,
María Luisa Martín Mateos, Ramón García Sanz, María Teresa Cibeira, María Luisa Martín Ramos, María Belén Vidriales,
María Angeles Montalbán, Juan-Jose Lahuerta, Joan Bladé, and Jesús F. San Miguel
Oral Session: Myeloma - Therapy, excluding Transplantation: Randomized Trials
Time: 7:30 AM
Location: Auditorium-320 (Orange County Convention Center)
Abstract No.: 309
www.myeloma.org
(800) 452 - CURE (2873)
Improved Outcome with Total Therapy 3 (TT3) In Comparison with Total Therapy 2 (TT2) Can Be Traced to GEP70-Defined
High-Risk Disease with Trisomy of 1q21 and Modest but Not Marked Hyper-Activation of the Proteasome Gene PSMD4
John Shaughnessy Jr., Pingping Qu, Erming Tian, Bijay Nair, Sarah Waheed, Yazan Alsayed, Frits van Rhee, John Crowley,
and Bart Barlogie
Oral Session: Myeloma - Biology and Pathophysiology, excluding Therapy: Genomic and Proteomic Profiling
Time: 7:30 AM
Location: 414 AB (Orange County Convention Center)
Abstract No.: 303
Development of Bortezomib Induced Peripheral Neuropathy (BiPN) In Multiple Myeloma:
Incidence and Molecular Characterization In Newly Diagnosed Patients Treated with Bortezomib
Annemiek Broyl, Sophie Corthals, Joost L.M. Jongen, Bronno van der Holt, Rowan Kuiper, Yvonne de Knegt, Laila el Jarari,
Uta Bertsch, Henk Lokhorst, Brian GM Durie, Hartmut Goldschmidt, and Pieter Sonneveld
Oral Session: Myeloma - Biology and Pathophysiology, excluding Therapy: Genomic and Proteomic Profiling
Time: 7:45 AM
Location: 414 AB (Orange County Convention Center)
Abstract No.: 304
Maintenance Treatment with Lenalidomide After Transplantation for MYELOMA: Final Analysis of the IFM 2005-02.
Michel Attal, Valerie Lauwers, Gerald Marit, Denis Caillot, Thierry Facon, Cyrille Hulin, Philippe Moreau, Claire Mathiot,
Murielle Roussel, Catherine Payen, H. Avet-Loiseau, and Jean Luc Harousseau
Oral Session: Myeloma - Therapy, excluding Transplantation: Randomized Trials
Time: 7:45 AM
Location: Auditorium-320 (Orange County Convention Center)
Abstract No.: 310
Bortezomib-Based Induction Therapy Followed by Autologous Stem Cell Transplantation and Maintenance Therapy
with Bortezomib Improves Outcome In Myeloma Patients with Gain 1q21 and t(4;14) - a Subgroup Analysis
of the HOVON-65/GMMG-HD4 Trial
Hartmut Goldschmidt, Kai Neben, Uta Bertsch, Thomas Hielscher, Bronno van der Holt, Dirk Hose, Laila el Jarari, Hans Salwender,
Igor Wolfgang Blau, Michael Pfreundschuh, Ulrich Duehrsen, Katja Weisel, Hans Martin, Walter Lindemann, Christian Teschendorf,
Mathias Haenel, Christof Scheid, Helgi van de Velde, Hans Guenter Derigs, Martin Hoffmann, Norma Peter, Martin Kaufmann,
Ingo Schmidt-Wolf, Anna Jauch, Henk M Lokhorst, and Pieter Sonneveld
Oral Session: Myeloma - Biology and Pathophysiology, excluding Therapy: Genomic and Proteomic Profiling
Time: 8:00 AM
Location: 414 AB (Orange County Convention Center)
Abstract No.: 305
Optimising Bone Disease In Myeloma; Zoledronic Acid Plus Thalidomide Combinations Improves Survival and
Bone Endpoints: Results of the MRC Myeloma IX Trial
Gareth J Morgan, Faith E. Davies, Walter M. Gregory, Sue E. Bell, Alexander J. Szubert, Mark T. Drayson, John Ashcroft, Roger G. Owen,
Gordon Cook, Fiona M. Ross, Graham H. Jackson, Nigel H. Russell, and J. Anthony Child
Oral Session: Myeloma - Therapy, excluding Transplantation: Randomized Trials
Time: 8:00 AM
Location: Auditorium-320 (Orange County Convention Center)
Abstract No.: 311
A Phase III Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous
Administration of Bortezomib In Patients with Relapsed Multiple Myeloma
Philippe Moreau, Halyna V .Pylypenko, Sebastian Grosicki, Evgeniy E. Karamanesht, Xavier Leleu, Maria E Grishunina,
Grigoriy B. Rekhtman, Zvenyslava Masliak, Tadeusz Robak, Anna V Shubina, Jean-Paul Fermand, Martin Kropff, James Cavet,
Sudha Parasuraman, Huaibao Feng, Donna M. Skee, Helgi van de Velde, William M. Deraedt, and Jean-Luc Harousseau
Oral Session: Myeloma - Therapy, excluding Transplantation: Randomized Trials
Time: 8:15 AM
Location: Auditorium-320 (Orange County Convention Center)
Abstract No.: 312
www.myeloma.org
(800) 452 - CURE (2873)
Prognostic Impact of Genetic Subgroups and Development of Gene Classifiers for Response, PFS and OS In Multiple Myeloma
Patients Treated with Bortezomib or Conventional Agents In HOVON65/GMMG-HD4 Trial
Annemiek Broyl, Rowan Kuiper, Martin H. van Vliet, Erik H. van Beers, Yvonne de Knegt, Bronno van der Holt, Laila el Jarari,
Berna Beverloo, H. Lokhorst, Sonja Zweegman, George Mulligan, Hartmut Goldschmidt, Mark van Duin, and Pieter Sonneveld
Oral Session: Myeloma - Biology and Pathophysiology, excluding Therapy II
Time: 10:30 AM
Location: 414 AB (Orange County Convention Center)
Abstract No.: 445
Comparing Toxicities and Survival Outcomes with Total Therapy 4 (TT4) for 70-Gene (R70)-Defined Low-Risk Multiple
Myeloma (MM) to Results Obtained with Total Therapy 3 Protocols TT3A and TT3B
Elias J. Anaissie, Frits van Rhee, Antje Hoering, Sarah Waheed, Yazan Alsayed, Nathan Petty, Monica Grazziutti, John Crowley,
and Bart Barlogie
Oral Session: Clinical Results - Autologous Transplantation: Clinical Developments in Leukemia, Myeloma and Lymphoma
Time: 10:45 AM
Location: 109A (Orange County Convention Center)
Abstract No.: 368
Selectin Inhibition Disrupts Multiple Myeloma Cells Interaction with the Bone Marrow Microenvironment and
Sensitizes Them to Therapy
Abdel Kareem A. Azab, Phong Quang, Feda Azab, John Magnani, John Patton, Theodore Smith, Arun Sarkar, Patricia Maiso,
Hai T. Ngo, Aldo M. Roccaro, Antonio Sacco, Yang Liu, Yong Zhang, Brittany Morgan, Kenneth C. Anderson, Andrew L. Kung,
Ruben Carrasco, and Irene M. Ghobrial
Oral Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Multiple Myeloma - Microenvironment and New Animal
Models
Time: 11:00 AM
Location: 314 (Orange County Convention Center)
Abstract No.: 453
The Immunomodulatory Drugs Lenalidomide and Pomalidomide Inhibit Multiple Myeloma-Induced Osteoclast Formation
and RANKL/OPG Ratio In Myeloma Microenvironment Targeting the Expression of Adhesion Molecules
Marina Bolzoni, Manuela Abeltino, Paola Storti, Sabrina Bonomini, Luca Agnelli, Katia Todoerti, Antonino Neri, Vittorio Rizzoli,
and Nicola Giuliani
Oral Session: Myeloma - Biology and Pathophysiology, excluding Therapy II
Time: 11:15 AM
Location: 414 AB (Orange County Convention Center)
Abstract No.: 448
Lenalidomide Targets Myeloma Cells Preferentially During Prolonged Early G1 Arrest but Not Synchronization Into S Phase
by Selective and Reversible Inhibition of CDK4/CDK6 through Loss of IRF-4
Xiangao Huang, Maurizio Di Liberto, David Jayabalan, Mohamad Hussein, Sophia Randolph, Ruben Niesvizky, and Selina Chen-Kiang
Oral Session: Myeloma - Biology and Pathophysiology, excluding Therapy II
Time: 11:30 AM
Location: 414 AB (Orange County Convention Center)
Abstract No.: 449
Lenalidomide Decreases PD-1 Expression, Depletes Regulatory T-Cells and Improves Cellular Response
to a Multiple Myeloma/ Dendritic Cell Fusion Vaccine In Vitro
Katarina Luptakova, Brett Glotzbecker, Heidi Mills, Dina Stroopinsky, Baldev Vasir, Jacalyn Rosenblatt, Donald Kufe,
and David Avigan
Oral Session: Tumor Immunotherapy: Clinical Trials and Experimental Results Using Human Cells or Antigens
Time: 11:45 AM
Location: 109B (Orange County Convention Center)
Abstract No.: 492
www.myeloma.org
(800) 452 - CURE (2873)
Phase IIIb UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based
Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients
Ruben Niesvizky, Ian W. Flinn, Robert M. Rifkin, Nashat Y. Gabrail, Veena Charu, Billy Clowney, James Essell, Yousuf A. Gaffar,
Thomas A. Warr, Rachel Neuwirth, Deyanira Corzo, and James A. Reeves
Oral Session: Myeloma - Therapy, excluding Transplantation: Myeloma Phase II/III Trials
Time: 2:45 PM
Location: Auditorium-320 (Orange County Convention Center)
Abstract No.: 619
Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide
(VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors
Antonio Palumbo, Sara Bringhen, Maide Cavalli, Roberto Ria, Massimo Offidani, Francesca Patriarca, Chiara Nozzoli,
Tommasina Guglielmelli, Giulia Benevolo, Vincenzo Callea, Renato Zambello, Giuseppe Pietrantuono, Luca De Rosa,
Anna Marina Liberati, Claudia Crippa, Giulia Perrone, Fabrizio Ciambelli, Angelo Michele Carella, Salvatore Palmieri,
Milena Gilestro, Valeria Magarotto, Maria Teresa Petrucci, Pellegrino Musto, Gianluca Gaidano, and Mario Boccadoro
Oral Session: Myeloma - Therapy, excluding Transplantation: Myeloma Phase II/III Trials
Time: 3:00 PM
Location: Auditorium-320 (Orange County Convention Center)
Abstract No.: 620
Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma
Benedetto Bruno, Barry Storer, Francesca Patriarca, Marcello Rotta, Roberto Sorasio, Bernardino Allione,
Fabrizio Carnevale-Schianca, Luisa Giaccone, Moreno Festuccia, Lucia Brunello, Paola Omedè, Federica Ferrando,
Sara Bringhen, Massimo Aglietta, Alessandro Levis, Nicola Mordini, Andrea Gallamini, Antonio Palumbo, Renato Fanin,
Rainer Storb, Ted Gooley, and Mario Boccadoro
Oral Session: Clinical Results - Allogeneic Matched Related Donor Transplantation
Time: 3:15 PM
Location: 110B (Orange County Convention Center)
Abstract No.: 525
Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide,
for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase II EVOLUTION Study
Shaji Kumar, Ian W. Flinn, Paul G. Richardson, Parameswaran Hari, Natalie Scott Callander, Stephen J. Noga, A. Keith Stewart,
Jonathan Glass, Robert M. Rifkin, Jeffrey L. Wolf, Jose Estevam, George Mulligan, Hongliang Shi, Iain J. Webb, and S. Vincent Rajkumar
Oral Session: Myeloma - Therapy, excluding Transplantation: Myeloma Phase II/III Trials
Time: 3:15 PM
Location: Auditorium-320 (Orange County Convention Center)
Abstract No.: 621
CD125-Expressing Myeloma: A Subgroup of Multiple Myeloma (MM) with Immature Phenotype, Endoplasmic Reticulum Stress
Response and Low Sensitivity to Bortezomib
Yawara Kawano, Yoshitaka Kikukawa, Miki Nakamura, Yutaka Okuno, Hiromichi Yuki, Shiho Fujiwara, Hiroaki Mitsuya, and
Hiroyuki Hata
Oral Session: Myeloma - Biology and Pathophysiology, excluding Therapy: Signaling Pathways
Time: 3:30 PM
Location: 414 AB (Orange County Convention Center)
Abstract No.: 616
A Phase III Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone
In Patients 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs
Fixed-Duration Regimens
Antonio Palumbo, Michel Delforge, John Catalano, Roman Hájek, Martin Kropff, Maria Teresa Petrucci, Zhinuan Yu, Lindsey Herbein,
Jay M. Mei, Christian J. Jacques, and Meletios A. Dimopoulos
Oral Session: Myeloma - Therapy, excluding Transplantation: Myeloma Phase II/III Trials
Time: 3:30 PM
Location: Auditorium-320 (Orange County Convention Center)
Abstract No.: 622
www.myeloma.org
(800) 452 - CURE (2873)
Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma
Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results
Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Sue E. Bell, Alex J. Szubert, Nuria Navarro-Coy, Mark T. Drayson, Roger G. Owen,
Gordon Cook, Fiona M. Ross, Graham H. Jackson, and J. Anthony Child
Oral Session: Myeloma - Therapy, excluding Transplantation: Myeloma Phase II/III Trials
Time: 3:45 PM
Location: Auditorium-320 (Orange County Convention Center)
Abstract No.: 623
Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell
Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients:
Primary Results of the IFM 2008 Phase II Study
Murielle Roussel, Hervé Avet-Loiseau, Philippe Moreau, Anne Huynh, Lotfi Benboubker, Cyrille Hulin, Gerald Marit, Xavier Leleu,
Brigitte Pegourie, Christophe Fruchart, Denis Caillot, Anne-Marie Stoppa, Thierry Facon, Jean-Luc Harousseau, and Michel Attal
Oral Session: Myeloma - Therapy, excluding Transplantation: Myeloma Phase II/III Trials
Time: 4:00 PM
Location: Auditorium-320 (Orange County Convention Center)
Abstract No.: 624
Proteomic Profiling of Multiple Myeloma (MM) Cells Using iTRAQ and Label-Free Quantitative Proteomics
for the Prediction of Complete or near Complete Response (CR/nCR) In Frontline Treatment with Lenalidomide,
Bortezomib, and Dexamethasone
Dominik Dytfeld, Malathi Kandarpa, John R. Strahler, Dattatreya Mellacheruvu, Suchitra Subramani, Stephanie J. Kraftson,
Lambert Ngoka, Alexey Nesvizhskii, Arun Sreekumar, Paul G. Richardson, and Andrzej J. Jakubowiak
Oral Session: Myeloma - Biology and Pathophysiology, excluding Therapy: Signaling Pathways
Time: 4:00 PM
Location: 414 AB (Orange County Convention Center)
Abstract No.: 618
Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients
with High-Risk Cytogenetic Abnormalities
Michele Cavo, Sara Bringhen, Carolina Terragna, Paola Omedè, Giulia Marzocchi, Marina Ruggeri, Sandra Durante,
Maria Teresa Petrucci, Tommasina Guglielmelli, Giulia Benevolo, Vittorio Montefusco, Franco Narni, Antonietta Falcone,
Catello Califano, Anna Baraldi, Silvana Pasini, Piero Galieni, Fortunato Morabito, Mariella Grasso, Daniela Gottardi,
Vincenzo Rizzo, Mario Boccadoro, Nicoletta Testoni, and Antonio Palumbo
Oral Session: Myeloma - Biology and Pathophysiology, excluding Therapy III
Time: 4:30 PM
Location: 414 AB (Orange County Convention Center)
Abstract No.: 781
Bortezomib Induced BRCAness Sensitizes Multiple Myeloma Cells to PARP Inhibitors
Oral and Poster Abstracts
Paola Neri, Li Ren, Kathy Gratton, Erin Stebner, Carolyn J. Owen, Peter Duggan, Adnan Mansoor, Douglas A. Stewart,
and Nizar J. Bahlis
Oral Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Multiple Myeloma - Molecular Target-Based Therapy
Time: 5:00 PM
Location: 314 (Orange County Convention Center)
Abstract No.: 789
Combined Treatment with Bortezomib Plus Bafilomycin A1 Enhances Cytocidal Effect along with Induction of ER Stress
In Myeloma Cells: Crosstalk Among Proteasome, Autophagy-Lysosome, and ER Stress
Keisuke Miyazawa, Shota Moriya, Tomohiro Kawaguchi, Tadashi Ohtomo, Xiao-Fang Che, Munekazu Naito, Masahiro Itoh,
and Akio Tomoda
Poster Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 4058
Poster Board: III-837
www.myeloma.org
(800) 452 - CURE (2873)
Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma
Neil Dunavin, Joyce Habib, Gary Phillips, Patrick Elder, Meaghan Tranovich, Don M. Benson Jr., Craig C. Hofmeister, John C. Byrd,
Steven M. Devine, and Yvonne Efebera
Poster Session: Clinical Results - Autologous Transplantation: Poster III
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3564
Poster Board: III-343
Effect of the Cytochrome P450 3A4 Inducers, Rifampicin and Dexamethasone, on the Pharmacokinetic, Pharmacodynamic
and Safety Profile of Bortezomib In Patients with Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL)
Andrzej Hellmann, Simon A. Rule, Jan Walewski, Ofer Shpilberg, Huaibao Feng, Helgi van de Velde, Hamina Patel, Donna M. Skee,
Suzette Girgis, and Vernon Louw
Poster Session: Molecular Pharmacology, Drug Resistance: Poster III
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3983
Poster Board: III-762
Efficacy and Tolerability of CEP-18770 In Combination with Dexamethasone and Lenalidomide Using a SCID-Hu Model
of Multiple Myeloma (MM)
Eric Sanchez, Mingjie Li, Cathy Wang, Zhi-Wei Li, Haiming Chen, and James R. Berenson
Poster Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 4066
Poster Board: III-845
High Dose Therapy with Autologous Stem Cell Transplantation Vs Standard Dose Chemotherapy In Multiple Myeloma:
A Meta-Analysis
Florian Faußner, Markus Pfirrmann, and Wolfram Dempke
Poster Session: Clinical Results - Autologous Transplantation: Poster III
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3559
Poster Board: III-338
The HIV Protease Inhibitor Nelfinavir: A Unique Oral Drug That Inhibits the Proteasome and AKT-Phosphorylation,
Induces ER Stress and Sensitizes Bortezomib-Refractory Primary Myeloma Cells and Primary AML Cells towards Bortezomib
Christoph Driessen, Jürgen Bader, and Marianne Kraus
Poster Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 4069
Poster Board: III-848
Impact on Response and Survival of DNA Repair Single Nucleotide Polymorphisms In Relapsed or Refractory Multiple
Myeloma Patients Treated with Thalidomide
Carlos Fernández de Larrea, María Teresa Cibeira, Alfons Navarro, Tania Díaz, Dolors Fuster, Natalia Tovar, Laura Rosiñol, Mariano
Monzó, and Joan Bladé
Poster Session: Myeloma - Biology and Pathophysiology, excluding Therapy: Poster III
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 4041
Poster Board: III-820
Influence of Different Dosages of Cyclophosphamide on Stem Cell Mobilization and Engraftment In Newly Diagnosed
Multiple Myeloma Patients Treated with a Thalidomide Containing Regimen
Joost TM De Wolf, Gustaaf Van Imhoff, Gerwin A Huls, and Edo Vellenga
Poster Session: Clinical Care - Transplantation Regimen Toxicities and Engraftment: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3494
Poster Board: III-273
www.myeloma.org
(800) 452 - CURE (2873)
Insulin-Like Growth Factor 1 Potentiates the Cytotoxic Activity of Bortezomib Against Myeloma Cells
Ines Tagoug, Lars Jordheim, Anne-Laure Huber, Stephanie Herveau, Eva Matera, Serge Manié, and Charles Dumontet
Poster Session: Molecular Pharmacology, Drug Resistance: Poster III
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3987
Poster Board: III-766
Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24
Monoclonal Antibody with Augmented NK Cell Degranulation
Sun-Young Kong, Sabikun Nahar, Xian-Feng Li, Weihua Song, Yiguo Hu, Umesh Muchhal, John Desjarlais, Paul Richardson,
Nikhil C. Munshi, Kenneth C. Anderson, and Yu-Tzu Tai
Poster Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 4064
Poster Board: III-843
Lenalidomide In Combination with the Activin Receptor Type II Murine Fc Protein RAP-011: Preclinical Rationale
for a Novel Anti-Myeloma Strategy
Sonia Vallet, Kishan Patel, Diana Cirstea, Katie Luly, Samantha Pozzi, Loredana Santo, Homare Eda, Jasbir Seehra, Anuj Mahindra,
David T. Scadden, and Noopur Raje
Poster Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 4075
Poster Board: III-854
Lenalidomide Maintenance Following Non Myeloablative Allogeneic Stem Cell Transplantation In Patients
with Multiple Myeloma: Results of the HOVON 76 Study
Monique C. Minnema, Evelien Kneppers, Ronnie van Der Holt, Marie Jose Kersten, Sonja Zweegman, Ellen Meijer, Edo Vellenga,
Tuna Mutis, Petra Cornelisse, and Henk Lokhorst
Poster Session: Clinical Results - Allogeneic Matched Related Donor Transplantation: Poster I
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3502
Poster Board: III-281
Lenalidomide Upregulates CXCR4 on CD34+ Hematopoietic Cells Resulting In Increased Binding to Bone Marrow Niche
and Inhibiting Mobilization Into Peripheral Blood In Multiple Myeloma Patients
Shirong Li, Rentian Feng, Huihui Ma, G. David Roodman, Markus Y. Mapara, and Suzanne Lentzsch
Poster Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 4079
Poster Board: III-858
Multiple Myeloma (MM) Highly Expresses CGEN-928 and the Anti-CGEN-928 TM21 Antibody Markedly Inhibits the Growth
of MM Cells and Enhances the Anti-Myeloma Effects of Dexamethasone, Melphalan and Bortezomib
Haiming Chen, Mingjie Li, Cathy Wang, Jessica Wang, Eric Sanchez, Zhi-Wei Li, Benjamin Bonavida, Ofer Levy, Liat Dassa,
Gady Cojocaru, James R. Berenson, and Zurit Levine
Poster Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 4067
Poster Board: III-846
A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and
Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients
Antonio Palumbo, Federica Cavallo, Izhar Hardan, Giovannino Ciccone, Alessandra Larocca, Maide Cavalli, Jacopo Peccatori,
Angelo Michele Carella, Annamaria Brioli, Anna Maria Cafro, Francesca Patriarca, Agostina Siniscalchi, Sara Pezzatti,
Claudia Crippa, Vittorio Montefusco, Anna Levi, Marina Ruggeri, Tommaso Caravita, Dina Ben Yehuda, Francesco Di Raimondo,
and Mario Boccadoro
Poster Session: Clinical Results - Autologous Transplantation: Poster III
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3573
Poster Board: III-352
www.myeloma.org
(800) 452 - CURE (2873)
Prognostic Impact of Cytogenetic Abnormalities On Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated with
Thalidomide-Dexamethasone Incorporated Into Double Autologous Stem-Cell Transplantation: An Analysis of 593 Patients
Elena Zamagni, Nicoletta Testoni, Carolina Terragna, Paola Tacchetti, Mauro Fiacchini, Francesca Patriarca, Patrizia Tosi,
Francesco Di Raimondo, Giulia Marzocchi, Maria Teresa Petrucci, Lucio Catalano, Sandra Durante, Silvestro Volpe, Monica Galli,
Luciano Masini, Antonio Ledda, Annamaria Brioli, Claudia Crippa, Alessandro Gozzetti, Franco Narni, Catello Califano,
Claudia Cellini, Sara Bringhen, Giuliana Leopardi, Lucia Pantani, Michela Ceccolini, Massimo Offidani, Giulia Perrone,
Beatrice Anna Zannetti, Michele Baccarani, and Michele Cavo
Poster Session: Clinical Results - Autologous Transplantation: Poster III
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3562
Poster Board: III-341
Role of Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma
Relapsing After Autograft: a Donor Versus No Donor Analysis
Francesca Patriarca, Hermann Einsele, Francesco Spina, Benedetto Bruno, Chiara Nozzoli, Miriam Isola, Alessandra Sperotto,
Andrea Nozza, Fortunato Morabito, Gernot Stuhler, Moreno Festuccia, Alberto Bosi, Renato Fanin, and Paolo Corradini
Poster Session: Clinical Results - Alternative Donor Transplantation: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3534
Poster Board: III-313
Tablet-Based Assessment of Fatigue, Depression, and Pain In Myeloma Patients: Cohort Study of Inflammatory Cytokines
and QOL Measures In the Newly Diagnosed, Patients on Lenalidomide, and Survivors
Craig C. Hofmeister, Gisele Rieser, Mindy A Bowers, Lisa C. Merritt, Carli N. Greenfield, Yvonne A. Efebera, Don M. Benson Jr.,
Steven M. Devine, and Janet S. de Moor
Poster Session: Health Services and Outcomes Research: Poster III
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 3807
Poster Board: III-586
Targeting IRE1-XBP1 Pathway Is a Novel Therapeutic Strategy In Multiple Myeloma
Oral and Poster Abstracts
Naoya Mimura, Teru Hideshima, Gullu Gorgun, Diana Cirstea, Loredana Santo, Yiguo Hu, Claire Fabre, Martina Blumenthal,
Victor Tam, Nathalie L. Kertesz, Qingping Zeng, John B. Patterson, Nikhil C. Munshi, Paul Richardson, and Kenneth C. Anderson
Poster Session: Myeloma - Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 4074
Poster Board: III-853
TP53 Mutations In Relapsed/Refractory Multiple Myeloma (MM) Treated with Thalidomide (Thal) or Thalidomide
Combination Therapy
David Alan Westerman, Giada Zapparoli, Chelsee Hewitt, Kevin Lynch, Linda Mileshkin, Emma Link, Alexander Dobrovic, and H.
Miles Prince
Poster Session: Myeloma - Biology and Pathophysiology, excluding Therapy: Poster III
Time: 6:00 PM-8:00 PM
Location: Hall A3/A4 (Orange County Convention Center)
Abstract No.: 4046
Poster Board: III-825
Phase II Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy
for Relapsed Multiple Myeloma. IFM 2009-02
Xavier Leleu, Michel Attal, Philippe Moreau, Alain Duhamel, Jean Paul Fermand, Mauricette Michalet, Catherine Traulle,
Gerald Marit, Murielle Roussel, Brigitte Kolb, Bertrand Arnulf, Laurent Garderet, Claire Mathiot, Margaret Macro,
Marie Odile Petillon, Brigitte Pegourie, Anne Marie Stoppa, Sabine Brechiniac, Bruno Royer, Lotfi Benboubker, Denis Caillot,
Martine Escoffre-Barbe, Cyrille Hulin, Jean-Luc Harousseau, Hervé Avet-Loiseau, and Thierry Facon
Oral Session: Myeloma - Therapy, excluding Transplantation: Myeloma Phase I/II Trials and Correlative Studies
Time: 6:15 PM
Location: 230 (Orange County Convention Center)
Abstract No.: 859
www.myeloma.org
(800) 452 - CURE (2873)
A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination
with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Ruben Niesvizky, Suzanne Lentzsch, Ashraf Z. Badros, Asher A. Chanan-Khan, Seema B. Singhal, Jeffrey A. Zonder, Ravi Vij,
Xiangao Huang, Maurizio DiLiberto, Rachel Courtney, M. Naveed Shaik, Sindy T. Kim, Sophia Randolph, Scott A. Ely,
and Selina Chen-Kiang
Oral Session: Myeloma - Therapy, excluding Transplantation: Myeloma Phase I/II Trials and Correlative Studies
Time: 6:30 PM
Location: 230 (Orange County Convention Center)
Abstract No.: 860
Molecular Remission After Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone
as Consolidation Therapy Following Double Autologous Transplantation for Multiple Myeloma: Results of a Qualitative
and Quantitative Analysis
Carolina Terragna, Elena Zamagni, Maria Teresa Petrucci, Sandra Durante, Francesca Patriarca, Franco Narni, Claudia Crippa,
Ausilia Gorgone, Tommaso Caravita, Giulia Perrone, Chiara Nozzoli, Luciano Masini, Vincenzo Callea, Immacolata Attolico,
Claudia Cellini, Sara Bringhen, Antonio Ledda, Vittorio Montefusco, Marina Martello, Giovanni Martinelli, Michele Baccarani,
and Michele Cavo
Oral Session: Myeloma - Therapy, excluding Transplantation: Myeloma Phase I/II Trials and Correlative Studies
Time: 6:45 PM
Location: 230 (Orange County Convention Center)
Abstract No.: 861
Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma:
Initial Results of Phase I/II MMRC Trial
Andrzej J. Jakubowiak, Dominik Dytfeld, Sundar Jagannath, David H. Vesole, Tara B. Anderson, Brian K. Nordgren, Daniel Lebovic,
Keith E. Stockerl-Goldstein, Kent A. Griffith, Melissa A. Hill, Colleen K. Harvey, Akari M. Dollard, Robert Ott, Susan L. Kelley,
Jennifer Barrickman, Michael Kauffman, and Ravi Vij
Oral Session: Myeloma - Therapy, excluding Transplantation: Myeloma Phase I/II Trials and Correlative Studies
Time: 7:00 PM
Location: 230 (Orange County Convention Center)
Abstract No.: 862
Tuesday, December 7th
Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma:
Interim Results of a Phase II Study
Paul G. Richardson, Philippe Moreau, Andrzej J. Jakubowiak, Thierry Facon, Sundar Jagannath, Ravi Vij, Donna E. Reece,
Darrell J. White, Marc S. Raab, Lotfi Benboubker, Jean-Francois Rossi, Claire Tsao, John Fry, David Berman, Anil K. Singhal,
and Sagar Lonial
Oral Session: Myeloma - Therapy, excluding Transplantation: Myeloma and Amyloidosis - Novel Drugs
Time: 7:45 AM
Location: Auditorium-320 (Orange County Convention Center)
Abstract No.: 986
A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis
Ashutosh D. Wechalekar, Efstathios Kastritis, Giampaolo Merlini, Philip N. Hawkins, Meletios A. Dimopoulos, Julian D. Gillmore,
Simon D.J. Gibbs, and Giovanni Palladini
Oral Session: Myeloma - Therapy, excluding Transplantation: Myeloma and Amyloidosis - Novel Drugs
Time: 8:15 AM
Location: Auditorium-320 (Orange County Convention Center)
Abstract No.: 988
Combination of Bendamustine, Lenalidomide, and Dexamethasone In Patients with Refractory or Relapsed Multiple Myeloma
Is Safe and Highly Effective: Results of a Phase I Clinical Trial
Suzanne Lentzsch, Amy O'Sullivan, Ryan Kennedy, Navkiranjit Gill, Carrie Andreas, Diane Gardner, Silvana Lalo, Steve Burt,
Robert L. Redner, Robert Volkin, David Roodman, Markus Y. Mapara, Frank Viverette, Mounzer Agha, and Jeffrey A. Zonder
Oral Session: Myeloma - Therapy, excluding Transplantation: Myeloma and Amyloidosis - Novel Drugs
Time: 8:30 AM
Location: Auditorium-320 (Orange County Convention Center)
Abstract No.: 989
www.myeloma.org
(800) 452 - CURE (2873)
Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or
Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib
Irene M. Ghobrial, Edie Weller, Ravi Vij, Nikhil C. Munshi, Ranjit Banwait, Meghan Rourke, Robert L. Schlossman, Jacob P. Laubach,
Andrzej J. Jakubowiak, Renee Leduc, Stacey Chuma, Janet Kunsman, Akari M. Dollard, Diane Warren, Brianna Harris, Tiffany Poon,
Amy Sam, Scott J Rodig, Kenneth C. Anderson, and Paul G. Richardson
Oral Session: Myeloma - Therapy, excluding Transplantation: Myeloma and Amyloidosis - Novel Drugs
Time: 8:45 AM
Location: Auditorium-320 (Orange County Convention Center)
Abstract No.: 990
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated
with Lenalidomide-Based Regimen
Federica Cavallo, Francesco Di Raimondo, Izhar Harda, Barbara Lupo, Alessandra Romano, Lucio Catalano, Luca Baldini,
Tommasina Guglielmelli, Luciano Masini, Davide Rossi, Roberto Ria, Giulia Benevolo, Antonietta Pia Falcone, Norbert Pescosta,
Monica Galli, Anna Baraldi, Valter Redoglia, Mario Boccadoro, and Antonio Palumbo
Poster Session: Antithrombotic Therapy
Time: 12:00 PM-1:30 PM
Location: 414 AB (Orange County Convention Center)
Abstract No.: 1092
Poster Board: I-72
www.myeloma.org
(800) 452 - CURE (2873)
(800)452-CURE (2873)
www.myeloma.org
www.myeloma.org
(800) 452 - CURE (2873)